Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
Post Survey Best Practices
I am a(n)…
Select...
MD/DO
NP/RN
PA
Other
How many years have you been in practice?
Select...
1-5
6-10
11-15
16-20
Over 20
What is your practice setting?
Select...
Solo Practice
Group Practice
Hospital
Clinic
Academic
Other
Number of patients seen per month with...
Cardiovascular Disease?
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Diabetes?
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Kidney Disease (CKD)?
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Please rate the following:
Degree to which your educational expectations were met
Select...
Excellent
Above Average
Average
Fair
Poor
Relevance to your practice
Select...
Excellent
Above Average
Average
Fair
Poor
Effective faculty presenters
Select...
Excellent
Above Average
Average
Fair
Poor
Overall Presentation
Select...
Excellent
Above Average
Average
Fair
Poor
Please rate the degree to which the Learning Objectives were met.
Identify patients at risk for T2D, HF, and/or CKD who should be screened for CRM diseases to reduce diagnostic delays.
Select...
Completely
Mostly
Somewhat
Not at all
Describe the link between DM and CVD, including the impact on health outcomes.
Select...
Completely
Mostly
Somewhat
Not at all
Integrate principles of multidisciplinary care to diagnosis, treatment, and ongoing management of patients with CRM conditions.
Select...
Completely
Mostly
Somewhat
Not at all
Agree or Disagree?
The presentation was fair and balanced, free of commercial bias.
Select...
YES
NO
I feel more competent as a result of the presentation.
Select...
YES
NO
The presentation was scientifically rigorous.
Select...
YES
NO
The content contributed valuable information that will assist in improving patient outcomes
Select...
Strongly Agree
Agree
Unsure
Disagree
Strongly Disagree
Will you change your practice behaviors as a result of the presentation?
Select...
Absolutely
Probably
Unsure
Unlikely
No
What barriers to change do you foresee?
Cost
Insurance Coverage
Formulary
Patient Compliance
Time with Patient
None
Other
If Other
What was your level of knowledge on this subject?
Before the presentation
Select...
None
Little
Some
Considerable
Expert
After the presentation
Select...
None
Little
Some
Considerable
Expert
What do you need to learn more about on this topic?
Which of the following is true about use of SGLT-2 inhibitors in CRM diseases?
Select...
SGLT-2 inhibitors are only indicated for patients who have T2D and HF
SGLT-2 inhibitors reduce CV mortality and HF hospitalizations as a class effect.
All SGLT-2 inhibitors have been studied in a population with CKD and no diabetes.
All SGLT-2 inhibitors are approved for use in patients with HF, regardless of diabetes status.
How confident do you feel in your response to the previous question?
Select...
Very confident
Confident
Somewhat confident
Not confident
Submit